These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9312168)

  • 1. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.
    Okuda K; D'Andrea A; Etten RA; Griffin JD
    J Clin Invest; 1997 Oct; 100(7):1708-15. PubMed ID: 9312168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein.
    Okuda K; D'Andrea A; Van Etten RA; Griffin JD
    Blood; 1998 Nov; 92(10):3848-56. PubMed ID: 9808578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model to evaluate Raf signaling in hematopoietic cells.
    Okuda K
    Int J Oncol; 2013 Sep; 43(3):903-10. PubMed ID: 23820731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
    Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.
    Voss J; Posern G; Hannemann JR; Wiedemann LM; Turhan AG; Poirel H; Bernard OA; Adermann K; Kardinal C; Feller SM
    Oncogene; 2000 Mar; 19(13):1684-90. PubMed ID: 10763825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain.
    Joneja B; Wojchowski DM
    J Biol Chem; 1997 Apr; 272(17):11176-84. PubMed ID: 9111017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation.
    Showers MO; Moreau JF; Linnekin D; Druker B; D'Andrea AD
    Blood; 1992 Dec; 80(12):3070-8. PubMed ID: 1467516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.
    Smith KM; Van Etten RA
    J Biol Chem; 2001 Jun; 276(26):24372-9. PubMed ID: 11320088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors.
    Ghaffari S; Kitidis C; Fleming MD; Neubauer H; Pfeffer K; Lodish HF
    Blood; 2001 Nov; 98(10):2948-57. PubMed ID: 11698276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
    Arlinghaus RB
    Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
    Carlesso N; Griffin JD; Druker BJ
    Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
    Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
    Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.